X4 Posts Narrower Q3 Loss, $187.7M Cash, and Details K2 Loan Covenants
XFOR sits 33% above its 52-week low of $2.43.
Summary
X4 narrowed its Q3 2026 loss to $20.2M from $29.8M and ended September with $187.7M in cash and securities. The 10-Q also lays out the full terms of the October K2 refinancing, including a $15M conversion at $3.2341 and cash and revenue covenants that begin in 2027 and 2029.
Key Events · Earnings and Guidance · XFOR
-
Q3 Loss Narrows on Cost Cuts
Net loss was $20.2M for Q3 2026 versus $29.8M a year earlier, with R&D down to $13.3M from $17.3M and G&A down to $9.1M from $11.6M after the 65% headcount reduction.
-
Product Revenue Nearly Doubles
Net product revenue rose to $2.8M in Q3 2026 from $1.6M, and to $7.6M for the nine months from $4.3M, driven by more patients on XOLREMDI.
-
Cash Covers 12 Months, Burn $60.6M
Cash, equivalents and short-term marketable securities totaled $187.7M at September 30, 2026 against $60.6M of nine-month operating cash use; management says funding lasts at least 12 months.
-
K2 Loan Terms and Covenants Detailed
The $150M K2 facility funded an $80M first tranche on October 7, 2026 to repay Hercules; it carries 8.55% floor plus 1.55% over prime, 1.0% PIK, and a $15M conversion option at $3.2341 per share, maturing October 1, 2030.
Analysis · XFOR · Life Sciences
X4's third-quarter loss narrowed to $20.2M from $29.8M a year ago as restructuring cut R&D and G&A, and product revenue grew to $2.8M from $1.6M. The balance sheet carries $187.7M of cash and securities against a $56.6M nine-month operating burn, which management says funds operations and debt for at least 12 months. The bigger read-through is the K2 loan: the filing quantifies a $150M facility ($80M drawn October 7, 2026 to retire Hercules), a 1.0% PIK component, and a $15M conversion option at $3.2341 per share. The new covenants matter — starting October 1, 2027, if market cap is below $800M the company must hold unrestricted cash equal to 75% of outstanding obligations (dropping to 40% after conditions), and from April 1, 2029 it must hit 50% of board-projected net product revenue. Those are real constraints on a company whose product revenue is still under $10M a year.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XFOR was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $321.2M. The 52-week trading range was $2.43 to $4.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.